Sino Biopharmaceutical Limited (SBHMY) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Wan Chai, 홍콩. 현재 CEO는 S. Y. Tse.
SBHMY 을(를) 보유 IPO 날짜 2017-09-05, 24,379 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $14.2B.
Sino Biopharmaceutical Limited is an investment holding company and research and development pharmaceutical conglomerate headquartered in Hong Kong, operating primarily in the People's Republic of China. The company develops and commercializes a diverse portfolio of pharmaceutical products across multiple therapeutic areas, including oncology, cardio-cerebral vascular, hepatitis, orthopedic, and respiratory medicines, as well as advanced chemical formulations and generic pharmaceuticals. Beyond pharmaceutical manufacturing, the company operates an integrated healthcare ecosystem encompassing hospital operations, pharmaceutical distribution, optometry services, health food production, medical device development, and health information consultancy. Through its three main business segments—Modernised Chinese Medicines and Chemical Medicines, Investment, and Others—Sino Biopharmaceutical serves patients and healthcare providers across China with both traditional and contemporary therapeutic solutions. The company was incorporated in 2000 and maintains a comprehensive value chain from research and development through distribution and patient care services.
